109 related articles for article (PubMed ID: 35808966)
1. Deep-Penetrating Triple-Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models.
Tang X; Du X; Yu Y; Qin M; Qian L; Zhang M; Yang Y; Yu Q; Gan Z
Small; 2022 Aug; 18(31):e2202834. PubMed ID: 35808966
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma.
Murata Y; Mizuno S; Kishiwada M; Uchida K; Noguchi D; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Kuriyama N; Sakurai H; Isaji S
Pancreatology; 2021 Dec; 21(8):1482-1490. PubMed ID: 34452821
[TBL] [Abstract][Full Text] [Related]
3. Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma.
Xiao H; Li X; Li B; Zhong Y; Qin J; Wang Y; Han S; Ren J; Shuai X
Acta Biomater; 2023 Apr; 161():265-274. PubMed ID: 36893956
[TBL] [Abstract][Full Text] [Related]
4. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.
Luo Y; Li C; Zhang Y; Liu P; Chen H; Zhao Z; Wang Y; Zhou Z; Song H; Su B; Li C; Li X; Zhang T; You H; Wu Y; Tian Z; Zhang S; Guo Y; Fan H; Chen Q; Jiang C; Sun T
Acta Biomater; 2023 Sep; 167():387-400. PubMed ID: 37276955
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.
Confeld MI; Mamnoon B; Feng L; Jensen-Smith H; Ray P; Froberg J; Kim J; Hollingsworth MA; Quadir M; Choi Y; Mallik S
Mol Pharm; 2020 Aug; 17(8):2849-2863. PubMed ID: 32521162
[TBL] [Abstract][Full Text] [Related]
6. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy.
Jaseanchiun W; Kato H; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
Pancreatology; 2019 Mar; 19(2):307-315. PubMed ID: 30738764
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes.
Hayasaki A; Murata Y; Usui M; Hibi T; Fujii T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Uchida K; Isaji S
Biomed Res Int; 2019; 2019():5738614. PubMed ID: 31080824
[TBL] [Abstract][Full Text] [Related]
8. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
[TBL] [Abstract][Full Text] [Related]
9. Prodrug Nanosensitizer Overcomes the Radiation Resistance of Hypoxic Tumor.
Qian L; Li Q; Ding Z; Luo K; Su J; Chen J; Zhu G; Gan Z; Yu Q
ACS Appl Mater Interfaces; 2022 Dec; 14(51):56454-56470. PubMed ID: 36525559
[TBL] [Abstract][Full Text] [Related]
10. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy.
Kim SS; Lee S; Lee HS; Bang S; Park MS
Abdom Radiol (NY); 2021 Feb; 46(2):655-666. PubMed ID: 32748250
[TBL] [Abstract][Full Text] [Related]
12. [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review].
Azria D; Seblain-El-Guerche C; Girard N; Hennequin C; Huguet F
Bull Cancer; 2008 Nov; 95(11):1116-30. PubMed ID: 19036684
[TBL] [Abstract][Full Text] [Related]
13. Stromal Homeostasis-Restoring Nanomedicine Enhances Pancreatic Cancer Chemotherapy.
Yu N; Zhang X; Zhong H; Mu J; Li X; Liu T; Shi X; Liang XJ; Guo S
Nano Lett; 2022 Nov; 22(21):8744-8754. PubMed ID: 36279310
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
Song H; Jiang C
Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
[TBL] [Abstract][Full Text] [Related]
15. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
[TBL] [Abstract][Full Text] [Related]
16. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.
Bian S; Dong H; Zhao L; Li Z; Chen J; Zhu X; Qiu N; Jia X; Song W; Li Z; Zheng S; Wang H; Song P
Adv Sci (Weinh); 2022 Oct; 9(29):e2201931. PubMed ID: 36026578
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma.
Hayasaki A; Murata Y; Usui M; Hibi T; Ito T; Iizawa Y; Kato H; Tanemura A; Azumi Y; Kuriyama N; Kishiwada M; Mizuno S; Sakurai H; Yoshida T; Isaji S
Pancreas; 2018 Apr; 47(4):390-399. PubMed ID: 29517632
[TBL] [Abstract][Full Text] [Related]
18. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer.
Tong QS; Miao WM; Huang H; Luo JQ; Liu R; Huang YC; Zhao DK; Shen S; Du JZ; Wang J
Small; 2021 Jul; 17(29):e2101208. PubMed ID: 34145747
[TBL] [Abstract][Full Text] [Related]
19. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer-associated Cathepsin E as a drug activator.
Abd-Elgaliel WR; Cruz-Monserrate Z; Wang H; Logsdon CD; Tung CH
J Control Release; 2013 May; 167(3):221-7. PubMed ID: 23422726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
